文献速递妇科

Linzagolix与亮丙瑞林治疗日本子宫肌瘤女性的3期随机对照非劣效试验

Linzagolix versus leuprorelin in Japanese women with uterine leiomyomas: a phase 3, randomized, active-controlled, non-inferiority trial.
PubMed 文献 · Hum Reprod · 2026-01-01

该3期随机双盲非劣效试验纳入287例子宫肌瘤伴月经过多的日本绝经前女性,比较口服linzagolix 200mg每日一次与皮下亮丙瑞林1.88mg每4周一次治疗24周的疗效与安全性。主要终点为治疗第6-12周PBAC总分<10的患者比例,linzagolix组为89.9%,亮丙瑞林组为90.8%,差异-0.9%(95%CI -8.6,6.9),达到非劣效。Linzagolix起效更快,median至PBAC<10时间为6.0天 vs 20.0天(P=0.023),且无 flare-up 效应,停药后雌二醇和月经恢复更早。

要点

  • Linzagolix 200mg每日一次治疗子宫肌瘤月经过多24周疗效非劣于亮丙瑞林1.88mg每4周一次。
  • Linzagolix起效更快,至PBAC<10的中位时间6.0天 vs 20.0天(P=0.023),无 flare-up。
  • 停药后linzagolix组雌二醇、月经及BMD下降恢复更早,或利于有妊娠计划者。

核心结论

  • Linzagolix 200mg每日一次治疗24周对子宫肌瘤月经过多的疗效非劣于亮丙瑞林,且起效更快、停药后恢复更早。

研究设计与样本

  • 3期、活性对照、多中心、随机、双盲、平行组、非劣效研究,日本开展,2022年10月至2024年8月。
  • 共287例患者按1:1随机至口服linzagolix 200mg每日一次(n=143)或皮下亮丙瑞林1.88mg每4周一次(n=144),治疗24周。
  • 随机按疼痛症状分层,使用交互式网络应答系统。

主要发现

  • 第6-12周PBAC总分<10比例:linzagolix组89.9%(95%CI 83.7,94.4),亮丙瑞林组90.8%(84.7,95.0),差异-0.9%(-8.6,6.9),非劣效界值-15%。
  • 至PBAC总分<10的中位时间linzagolix组6.0天,显著短于亮丙瑞林组20.0天(P=0.023)。
  • 24周内疼痛、血红蛋白、肌瘤/子宫体积及患者报告结局改善两组相当,linzagolix组疼痛和肌瘤/子宫体积下降更早。
  • linzagolix组第2周血浆雌二醇快速降至<20 pg/ml且维持至第24周,无flare-up效应;亮丙瑞林组出现flare-up。
  • 不良事件发生率linzagolix组97.2%、亮丙瑞林组96.5%;最常见不良事件分别为潮热(53.8%)和突破性出血(55.6%),多发生在治疗前28天。

关键数值与推荐

  • 主要终点非劣效界值为-15%。
  • 第6-12周PBAC总分<10比例linzagolix组89.9%(95%CI 83.7,94.4),亮丙瑞林组90.8%(84.7,95.0)。
  • 至PBAC总分<10中位时间6.0天 vs 20.0天(P=0.023)。
  • linzagolix组第2周雌二醇<20 pg/ml并维持至第24周。
  • 不良事件发生率97.2% vs 96.5%,潮热53.8% vs 突破性出血55.6%。

临床怎么用

  • Linzagolix 200mg每日一次可用作子宫肌瘤月经过多的24周治疗选择,疗效与亮丙瑞林相当且起效更快。
  • 快速缩小肌瘤和子宫体积的特点提示linzagolix可能适合术前预处理。
  • 停药后雌二醇和月经恢复更早,对有妊娠计划者可能有利。

局限性

  • 需进一步比较linzagolix与其他GnRH受体拮抗剂。
  • 需评估linzagolix(联合或不联合激素反向添加治疗)在 Japanese 子宫肌瘤伴月经过多女性中的长期安全性和疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: How does the efficacy of linzagolix (a gonadotropin-releasing hormone [GnRH] receptor antagonist) compare with leuprorelin (a GnRH agonist) for the treatment of heavy menstrual bleeding (HMB) in patients with uterine leiomyomas? SUMMARY ANSWER: Reductions in menstrual bleeding with linzagolix were rapidly achieved, non-inferior to leuprorelin at Weeks 6-12, and maintained over 24 weeks of treatment. WHAT IS KNOWN ALREADY: GnRH agonists are commonly used to manage the symptoms of uterine leiomyomas; however, they are also associated with bone mineral density (BMD) loss, an initial worsening of symptoms (flare-up effect), and delayed pituitary recovery after treatment cessation. Linzagolix is a GnRH receptor antagonist that may overcome the limitations of GnRH agonists, though comparative safety and efficacy have not yet been evaluated. STUDY DESIGN, SIZE, DURATION: This was a phase 3, active-controlled, multicentre, randomized, double-blind, parallel-group, non-inferiority study, conducted in Japan between October 2022 and August 2024. In total, 287 patients were randomized 1:1 to oral linzagolix 200 mg once daily (plus leuprorelin placebo; n = 143) or subcutaneous leuprorelin 1.88 mg every 4 weeks (plus linzagolix placebo; n = 144) for 24 weeks. Patients were randomized using an interactive web response system, stratified by the presence of pain symptoms. PARTICIPANTS/MATERIALS, SETTING, METHODS: Eligible patients were premenopausal women (aged ≥20 years) with uterine leiomyomas and HMB. Key assessments throughout the treatment period included menstrual bleeding (measured using the Pictorial Blood Loss Assessment Chart [PBAC]), pain (measured using a numeric rating scale), blood haemoglobin, myoma and uterine volumes (measured by transvaginal ultrasound), patient-reported symptom severity and quality of life, plasma oestradiol, adverse events (AEs), and BMD. At the end of treatment, patients entered a follow-up period of up to 24 weeks, during which plasma oestradiol, BMD, and menstrual recovery were assessed. The primary endpoint was the proportion of patients with a total PBAC score <10 from Weeks 6 to 12 of the treatment period (non-inferiority margin, -15%). MAIN RESULTS AND THE ROLE OF CHANCE: From Weeks 6 to 12, the proportion of patients with a total PBAC score <10 was 89.9% (95% CI, 83.7, 94.4) in the linzagolix group, which was non-inferior to 90.8% (84.7, 95.0) in the leuprorelin group (difference, -0.9% [-8.6, 6.9]). Reductions in menstrual bleeding were rapidly achieved with linzagolix; median time to a total PBAC score <10 was significantly shorter in the linzagolix group versus leuprorelin (6.0 vs 20.0 days; P = 0.023). Improvements in pain, haemoglobin, myoma/uterine volumes, and patient-reported outcomes were comparable between groups over 24 weeks, with earlier reductions in pain and myoma/uterine volumes observed in the linzagolix group. Mean plasma oestradiol levels were rapidly reduced to <20 pg/ml by Week 2 in the linzagolix group (without the flare-up effect seen in the leuprorelin group) and were maintained through Week 24. The incidence of AEs was comparable between the linzagolix and leuprorelin groups (97.2% and 96.5%, respectively). The most common AE was hot flush in the linzagolix group (53.8%) and breakthrough bleeding in the leuprorelin group (55.6%), and the incidence of these events was highest during the first 28 days of treatment. Following the end of study treatment, mean plasma oestradiol levels tended to recover earlier in the linzagolix group versus leuprorelin, which coincided with earlier recovery of hot flush AEs, reductions in BMD, and menstruation. LIMITATIONS, REASONS FOR CAUTION: Further studies are warranted to compare linzagolix with other GnRH receptor antagonists, and to evaluate the longer-term safety and efficacy of linzagolix, with or without hormonal add-back therapy, in Japanese women with uterine leiomyomas and HMB. WIDER IMPLICATIONS OF THE FINDINGS: This phase 3 study met its primary endpoint, and demonstrated the 24-week efficacy, safety, and pharmacodynamic effects of linzagolix in Japanese women with symptomatic uterine leiomyomas. While linzagolix offered comparable efficacy to leuprorelin over 24 weeks of treatment, its earlier onset of action may make linzagolix a favourable treatment option. In particular, rapid reductions in myoma and uterine volumes suggest that linzagolix may be a useful preoperative treatment. Moreover, earlier recovery of oestradiol levels and menstruation following linzagolix may be an important consideration for women planning pregnancy after treatment. Overall, these findings support the use of linzagolix over 24 weeks for the signs and symptoms of uterine leiomyomas. STUDY FUNDING/COMPETING INTEREST(S): Funding for the study and third-party medical writing support was provided by Kissei Pharmaceutical Co., Ltd. The study sponsor participated in the design of the study; the collection, analysis, and interpretation of data; and the development of the manuscript. Y.O. and T.H. report medical writing and clinical trial advisory fees from Kissei Pharmaceutical Co., Ltd. H.T. reports patent applications with Kissei Pharmaceutical Co., Ltd. H.T., A.K., and F.S. are employees of Kissei Pharmaceutical Co., Ltd. TRIAL REGISTRATION NUMBER: NCT05440383. TRIAL REGISTRATION DATE: 27 June 2022. DATE OF FIRST PATIENT’S ENROLMENT: 11 October 2022.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Osuga Y, Harada T, Takahashi H, et al. Linzagolix versus leuprorelin in Japanese women with uterine leiomyomas: a phase 3, randomized, active-controlled, non-inferiority trial. Hum Reprod. 2026. PMID: 42406777. doi:10.1093/humrep/deag106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。